文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

广东经治HIV-1 CRF55_01B感染者耐药特征

Characteristics of drug resistance in HIV-1 CRF55_01B from ART-experienced patients in Guangdong, China.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

研究对2013至2018年广东CRF55_01B感染者进行获得性耐药检测,共162例(4.78%)阳性。M184V和V179E分别为最常见NRTI和NNRTI耐药突变。79.01%患者对至少一类ART药物低度以上耐药,NNRTI类高度耐药比例高。

要点

  • CRF55_01B感染者中V179E突变频率达98.77%,M184V为43.83%。
  • 79.01%患者对至少一类ART药物低度以上耐药。
  • NNRTI类高度耐药:奈韦拉平70.99%,依非韦伦63.58%。

核心结论

  • 广东CRF55_01B感染且ART失败患者中耐药突变和耐药频率高。
  • 可考虑干预以减少ART的生态贡献。

研究设计与样本

  • 对CRF55_01B感染且病毒学失败患者立即进行获得性耐药检测。
  • 收集人口学和流行病学信息,用斯坦福HIVdb程序解读耐药突变和药物敏感性。

主要发现

  • 2013至2018年共鉴定162株(4.78%)CRF55_01B分离株。
  • NRTI耐药突变中最常见M184V(43.83%),其次K65R(23.46%)。
  • NNRTI耐药突变中最常见V179E(98.77%),其次K103N(47.53%)和Y181C(14.81%)。
  • 79.01%患者携带对三类ART药物中至少一类低度或以上耐药的突变。
  • PI耐药突变仅发现1例对奈非那韦低度耐药(0.62%)。

关键数值与推荐

  • NRTI高度耐药:拉米夫定58.64%,恩曲他滨58.02%。
  • NNRTI高度耐药:奈韦拉平70.99%,依非韦伦63.58%,利匹韦林22.22%,多拉韦林17.90%,依曲韦林4.32%。
  • 超过75%患者携带依非韦伦和奈韦拉平耐药突变。

临床怎么用

  • 对CRF55_01B感染且ART失败者应尽早行耐药检测。
  • 关注M184V、K65R、V179E、K103N和Y181C等突变。
  • NNRTI类耐药比例高,经验性用药需参考耐药结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HIV-1 acquired drug resistance (ADR) has become a critical clinical and public health issue. Recently, HIV-1 CRF55_01B has been found more frequently in the MSM population. OBJECTIVE: To investigate the characteristics of HIV-1 drug resistance mutations (DRMs) and the extent of changes in drug susceptibility among ART-experienced CRF55_01B-infected adults of Guangdong. METHODS: ADR was tested for immediately in CRF55_01B-infected patients with virological failure. Demographic and epidemiological information was collected. DRMs and antiretroviral susceptibility were interpreted using the Stanford University HIV Drug Resistance Database HIVdb program. RESULTS: Overall, 162 (4.78%) CRF55_01B isolates were identified from 2013 to 2018. Among DRMs, M184V (43.83%) was the most frequent NRTI DRM, followed by K65R (23.46%), and V179E (98.77%) was the most frequent NNRTI DRM, followed by K103N (47.53%) and Y181C (14.81%). According to the HIVdb program, 79.01% of the CRF55_01B-infected patients carried mutations conferring low-level or higher drug resistance to any of the three classes of ART drugs. Among PI DRMs, only one mutation affording low-level resistance to nelfinavir was found (0.62%). Among NRTI DRMs, a high proportion of high-level resistance to lamivudine (58.64%) and emtricitabine (58.02%) was found. As regards NNRTIs, more than 75% of patients carried efavirenz and nevirapine DRMs. The percentages of high-level resistance were 70.99%, 63.58%, 22.22%, 17.90% and 4.32% for nevirapine, efavirenz, rilpivirine, doravirine and etravirine, respectively. CONCLUSIONS: High frequencies of DRMs and resistance were observed among CRF55_01B-infected patients failing ART in Guangdong, and interventions may be considered to minimize ecological contributions to ART.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Lan Y, Xin R, Cai W, et al. Characteristics of drug resistance in HIV-1 CRF55_01B from ART-experienced patients in Guangdong, China. J Antimicrob Chemother. 2020. PMID: 32300784. doi:10.1093/jac/dkaa116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。